Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.04.2023 | Case report

Erenumab

Symmetrical drug-related intertriginous and flexural exanthema: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Gobel CH, et al. First Report of Symmetrical Drug-related Intertriginous and Flexural Exanthema (SDRIFE or Baboon Syndrome) After Erenumab Application for Migraine Prevention. Pain and Therapy 11 : 1483-1491, No. 4, Dec 2022. Available from: URL: https://www.springer.com/journal/40122 Gobel CH, et al. First Report of Symmetrical Drug-related Intertriginous and Flexural Exanthema (SDRIFE or Baboon Syndrome) After Erenumab Application for Migraine Prevention. Pain and Therapy 11 : 1483-1491, No. 4, Dec 2022. Available from: URL: https://​www.​springer.​com/​journal/​40122
Metadaten
Titel
Erenumab
Symmetrical drug-related intertriginous and flexural exanthema: case report
Publikationsdatum
01.04.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-37621-4

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Adalimumab

Case report

Rituximab

Case report

Ixekizumab